All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2020; the latest 2026-01-30.
From the record
Jin Medical International Ltd.'s filings since 2020 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2026-01-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-0.1% a year over 5 filed years; profitable in 5 of 5.
From the record
Jin Medical International Ltd.'s 5 filed years say what it did: revenue went from $21 million in fiscal 2021 to $21 million in fiscal 2025, down 0.1% a year; it rose in 2 of 4 years; the deepest fall was 12% from fiscal 2024 to fiscal 2025; net income was positive in 5 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 5.1% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-09-30, Jin Medical International Ltd.'s diluted share count grew about 5.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 4%: 4¢ of profit per shareholder dollar. Leverage 45%: owes 45¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-09-30, Jin Medical International Ltd. earned about 4 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 11 cents per dollar of everything the company owns. Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 45% of 26 in its family; net margin 5.8%.
From the record
Jin Medical International Ltd.'s standing among 26 graded names in its industry family: revenue of $21 million in fiscal 2025 ranks in the bottom 33% by size; a net margin of 5.8% ranks in the top 37%; revenue growth of 2.5% a year over the last 3 filed years ranks in the bottom 39% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Jin Medical International Ltd.'s leadership is put at 5.3 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-24 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 19 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 38% of 25 in its family for room to expand.
From the record
Jin Medical International Ltd.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 14% of its assets as net cash, bottom 46% of its family; cash from operations less capital spending is -18% of revenue (bottom 46%); a gross margin of 29.2% (bottom 18%); research spending of 7.5% of revenue (bottom 41%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 49% of 25 in its family for growth drivers.
From the record
Jin Medical International Ltd.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.5% a year over the last three filed years against -0.1% over all 5, speeding up (top 34% of its family); the newest year grew -12% (bottom 10%); research spending grew -6.3% a year (bottom 23%); capital spending grew 448.3% a year (top 2%) (its annual reports). Jin Medical International Ltd. reported 3 product lines in fiscal 2025: Wheelchair at $16 million (78%), Other Products at $3 million (13%), Wheelchair Components at $2 million (9%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 24% of 23 in its family for expectations against reality.
From the record
Jin Medical International Ltd.'s newest year against its own record: revenue of $21 million in fiscal 2025 came in 20.5% below the $26 million its prior three years' pace pointed to (bottom 10% of its family); net income of $1 million against a prior three-year average of $3 million (bottom 24%); a net margin of 5.8% against 14.8% before (bottom 37%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made